InterMune Inc. (ITMN) announced Tuesday morning that the on-going Phase 2b study conducted by Roche of ITMN-191 combined with standard of care PEGASYS and COPEGUS in HCV treatment-naive patients has been modified.
InterMune gapped down sharply Tuesday, but has since traded in a narrow range. The stock has slipped further in the last 10 minutes and is now down 2.31 at $11.71 on the highest volume in 6 months. InterMune has dropped to a 5 1/2 month low.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.